These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 24755473)

  • 41. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.
    Andronesi OC; Arrillaga-Romany IC; Ly KI; Bogner W; Ratai EM; Reitz K; Iafrate AJ; Dietrich J; Gerstner ER; Chi AS; Rosen BR; Wen PY; Cahill DP; Batchelor TT
    Nat Commun; 2018 Apr; 9(1):1474. PubMed ID: 29662077
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
    Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR
    Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy.
    Molenaar RJ; Wilmink JW
    J Histochem Cytochem; 2022 Jan; 70(1):83-97. PubMed ID: 34967233
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment.
    Subramani E; Radoul M; Najac C; Batsios G; Molloy AR; Hong D; Gillespie AM; Santos RD; Viswanath P; Costello JF; Pieper RO; Ronen SM
    Cancer Res; 2020 Nov; 80(22):5098-5108. PubMed ID: 32958546
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reductive carboxylation supports growth in tumour cells with defective mitochondria.
    Mullen AR; Wheaton WW; Jin ES; Chen PH; Sullivan LB; Cheng T; Yang Y; Linehan WM; Chandel NS; DeBerardinis RJ
    Nature; 2011 Nov; 481(7381):385-8. PubMed ID: 22101431
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications.
    Lee S; Urman A; Desai P
    Leuk Lymphoma; 2019 Nov; 60(11):2635-2645. PubMed ID: 30958073
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    Xu C; Ooi WF; Qamra A; Tan J; Chua BY; Ho SWT; Das K; Adam Isa ZF; Li Z; Yao X; Yan T; Xing M; Huang KK; Lin JS; Nandi T; Tay ST; Lee MH; Tan ALK; Ong X; Ashktorab H; Smoot D; Li S; Ng SC; Teh BT; Tan P
    Gut; 2020 Feb; 69(2):231-242. PubMed ID: 31068366
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The heterocyclic compound Tempol inhibits the growth of cancer cells by interfering with glutamine metabolism.
    Ye S; Xu P; Huang M; Chen X; Zeng S; Wang Q; Chen J; Li K; Gao W; Liu R; Liu J; Shao Y; Zhang H; Xu Y; Zhang Q; Zhong Z; Wei Z; Wang J; Hao B; Huang W; Liu Q
    Cell Death Dis; 2020 May; 11(5):312. PubMed ID: 32366855
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
    Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
    Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.
    Machida Y; Nakagawa M; Matsunaga H; Yamaguchi M; Ogawara Y; Shima Y; Yamagata K; Katsumoto T; Hattori A; Itoh M; Seki T; Nishiya Y; Nakamura K; Suzuki K; Imaoka T; Baba D; Suzuki M; Sampetrean O; Saya H; Ichimura K; Kitabayashi I
    Mol Cancer Ther; 2020 Feb; 19(2):375-383. PubMed ID: 31727689
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutant IDH1 inhibitors activate pSTAT3-Y705 leading to an increase in BCAT1 and YKL-40 levels in mutant IDH1-expressing cells.
    Bhattacharjee D; Balabhaskararao K; Jain N
    Biochim Biophys Acta Mol Cell Res; 2021 Oct; 1868(11):119114. PubMed ID: 34329662
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
    Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
    Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1.
    Zheng M; Sun W; Gao S; Luan S; Li D; Chen R; Zhang Q; Chen L; Huang J; Li H
    Oncotarget; 2017 Jul; 8(27):44255-44265. PubMed ID: 28498812
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Spatial-fluxomics provides a subcellular-compartmentalized view of reductive glutamine metabolism in cancer cells.
    Lee WD; Mukha D; Aizenshtein E; Shlomi T
    Nat Commun; 2019 Mar; 10(1):1351. PubMed ID: 30903027
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
    Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
    J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FASN deficiency induces a cytosol-to-mitochondria citrate flux to mitigate detachment-induced oxidative stress.
    Dai W; Wang Z; Wang G; Wang QA; DeBerardinis R; Jiang L
    Cell Rep; 2023 Aug; 42(8):112971. PubMed ID: 37578864
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
    Okoye-Okafor UC; Bartholdy B; Cartier J; Gao EN; Pietrak B; Rendina AR; Rominger C; Quinn C; Smallwood A; Wiggall KJ; Reif AJ; Schmidt SJ; Qi H; Zhao H; Joberty G; Faelth-Savitski M; Bantscheff M; Drewes G; Duraiswami C; Brady P; Groy A; Narayanagari SR; Antony-Debre I; Mitchell K; Wang HR; Kao YR; Christopeit M; Carvajal L; Barreyro L; Paietta E; Makishima H; Will B; Concha N; Adams ND; Schwartz B; McCabe MT; Maciejewski J; Verma A; Steidl U
    Nat Chem Biol; 2015 Nov; 11(11):878-86. PubMed ID: 26436839
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Sells.
    Badur MG; Muthusamy T; Parker SJ; Ma S; McBrayer SK; Cordes T; Magana JH; Guan KL; Metallo CM
    Cell Rep; 2018 Oct; 25(4):1018-1026.e4. PubMed ID: 30355481
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IDH1-Driven Reductive Carboxylation Supports Anchorage Independence.
    Cancer Discov; 2016 Jun; 6(6):570. PubMed ID: 27125548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.